A phase 1 trial of SGN‐CD70A in patients with CD70‐positive, metastatic renal cell carcinoma

K. Pal, Sumanta; Forero‐Torres, Andres; A. Thompson, John; C. Morris, John; Chhabra, Saurabh; Hoimes, Christopher; J. Vogelzang, Nicholas; E. Boyd, Thomas; Gustavo Bergerot, Paulo; J. Adashek, Jacob; Li, Hong; Yu, Xuesong; M. Gartner, Elaina; Carret, Anne‐Sophie; C. Smith, David

doi:10.1002/cncr.31912

Public

A phase 1 trial of SGN‐CD70A in patients with CD70‐positive, metastatic renal cell carcinoma

Published in Cancer • Jan 9, 2019

Authors:

Sumanta K. Pal

Andres Forero‐Torres

John A. Thompson

Abstract

BACKGROUND: Cluster of differentiation 70 (CD70) is frequently expressed in renal cell carcinoma (RCC) and has immunomodulatory properties. An antibody-drug conjugate targeting CD70, SGN-CD70A, was developed to treat patients with CD70-positive RCC. METHODS: The objective of this phase 1, open-label...

Subject

Medicine

Tolerability

Renal cell carcinoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!